Dr. Reddys Laboratories is currently trading at Rs. 4249.00, down by 48.00 points or 1.12% from its previous closing of Rs. 4297.00 on the BSE.
The scrip opened at Rs. 4300.00 and has touched a high and low of Rs. 4305.00 and Rs. 4220.00 respectively. So far 3197 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4337.00 on 14-Aug-2015 and a 52 week low of Rs. 2794.85 on 22-Aug-2014.
Last one week high and low of the scrip stood at Rs. 4337.00 and Rs. 4160.45 respectively. The current market cap of the company is Rs. 71975.44 crore.
The promoters holding in the company stood at 25.48% while Institutions and Non-Institutions held 43.67% and 13.81% respectively.
Dr Reddy's Laboratories (DRL) has initiated voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market, following 'Failed Dissolution Specifications'. Rivastigmine Tartrate Capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type or Parkinson's disease.
A total of 60 bottles of 2952 units are recalled on the direction of US Food and Drug Administration (USFDA). The batch was manufactured at the company’s Bachupally unit and the recall was initiated under 'Class II' classification.
Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1871.60 |
| Dr. Reddys Labs. | 1378.40 |
| Cipla | 1459.65 |
| Zydus Lifesciences | 1117.10 |
| Lupin | 2391.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: